Results 41 to 50 of about 25,915 (168)

A Multi‐Scale Computational Framework for Anti‐Persister Tuberculosis Drug Discovery

Chemical Biology &Drug Design, Volume 108, Issue 4, October 2026.
This review presents an integrated QSAR–scaffold design–docking–MD framework for discovering anti‐persister tuberculosis agents active in dormant granuloma‐like conditions. By targeting Mtb bioenergetics and prioritising dual NDH‐2/cytochrome bd oxidase inhibition, the workflow advances rational design of candidates with higher resistance barriers ...
Said Moshawih, Anguraj Moulishankar, Chee Yan Choo, Khang Wen Goh, Chrismawan Ardianto, Azam Che Idris, Long Chiau Ming   +6 more
wiley   +1 more source

Clinical guideline highlights for the hospitalist: Updates on the treatment of drug‐susceptible and drug‐resistant tuberculosis

Journal of Hospital Medicine, EarlyView.
Allison Stickles, Anna Poston‐Blahnik, Elizabeth Schlaudecker, Moises Huaman   +3 more
wiley   +1 more source

Diagnosis and Management of Infectious Encephalitis in Adults: Guidelines From the European Academy of Neurology and European Society of Clinical Microbiology and Infectious Diseases

European Journal of Neurology, Volume 33, Issue 10, October 2026.
ABSTRACT Background Encephalitis is difficult to diagnose and manage, posing a challenge to clinicians. Since the last European guidelines were published in 2010, novel causes have emerged, diagnostic processes have evolved and treatments assessed which need to be reflected in updated guidelines.
Julia Granerod, Johann Sellner, Jean‐Paul Stahl, Sylviane Defres, Alexandra Mailles, Erich Schmutzhard, Elisabeth Aurelius, Thomas Whitfield, Luca Massacesi, Maarten J. Titulaer, Pille Taba, Benedict D. Michael, Tehmina Bharucha, Lance Turtle, Brendan Sargent, Arina Tamborska, Jonathan Cattrall, Yun Huang, Eva Maria Hodel, Suzannah Lant, Glynn Webb, Rajish S. K. Shil, Shalley Dhar, Diederik van de Beek, Marie Studahl, Matthijs C. Brouwer, Uta Meyding‐Lamade, Ava Easton, Bhagteshwar Singh, Tom Solomon   +29 more
wiley   +1 more source

A Painful Purpuric Rash in a Febrile Smoker

JEADV Clinical Practice, EarlyView.
Eugerta Dilka, Ina Sotiri, Irda Rrugeja, Monika Fida   +3 more
wiley   +1 more source

Byrsonima crassifolia: Ethnobotany, Phytochemistry, and Pharmacology – An Update

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
Current knowledge on B. crassifolia is integrated, linking its phytochemical diversity with reported pharmacological activities and highlighting the therapeutic potential of this medicinal species. ABSTRACT Byrsonima crassifolia is a fruit‐bearing species widely distributed across tropical regions of the Americas with potential health applications ...
João de Jesus Oliveira Junior, Débora Luana Ribeiro Pessoa, Marilene Oliveira da Rocha Borges   +2 more
wiley   +1 more source

Tuberculosis Misdiagnosed as Bronchogenic Carcinoma: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT The patient, a 77‐year‐old male smoker, presented to the Emergency Department with dyspnea, cough, fever, night sweats, and 12 kg weight loss, initially suggesting COPD or lung cancer. Chest CT revealed a right upper lobe mass, pleural effusion, and lymphadenopathy, prompting suspicion of malignancy.
Pejman Hosseinzadeh, Sara Samadi, Shirin Taraz Jamshidi, Sayed Mortaza Fayez, Mahnaz Mozdourian   +4 more
wiley   +1 more source

Clinical profile and visual outcomes in ethambutol-induced toxic optic neuropathy

Indian Journal of Ophthalmology
Purpose: To characterize the severity of vision loss, dose-related adverse effects, and visual outcomes in ethambutol-induced toxic optic neuropathy (ETON) patients.
Jenil Sheth, Virender Sachdeva, Ashima Goyal, Aditi Parikh, Rohan Nalawade, Hardik Nanavati, Ramesh Kekunnaya   +6 more
doaj   +1 more source

Frequency of mutational changes in the embB among the ethambutol-resistant strains of Mycobacterium tuberculosis in Iran

Journal of Infection in Developing Countries, 2016
Introduction: Early detection of drug resistant tuberculosis is one of the main priorities of TB control program. Ethambutol (EMB) is a first-line anti-TB drug that is effective for preventing treatment failures caused by Mycobacterium tuberculosis ...
Faranak Rezaei, Mehri Haeili, Parviz Mohajeri, Abdolrazagh Hashemi Shahraki, Abbas Ali Imani Fooladi, Fatemeh Zahednamazi, Mohammad Mehdi Feizabadi   +6 more
doaj   +1 more source

Obstructive Jaundice due to a Periportal Tuberculous Mass Complicated by Anti‐Tuberculous Drug‐Induced Liver Injury: A Case Report From a Low‐Resource Setting

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Periportal tuberculous lymphadenitis with obstructive jaundice is rare and may mimic malignancy. We report a case of obstructive jaundice caused by a periportal tuberculous mass confirmed by fine‐needle aspiration and GeneXpert. Treatment was complicated by anti‐tuberculous drug‐induced liver injury.
Girma Deshimo Lema, Yemisrach Chanie, Mathewos Tesfaye Yanore, Segenet Bizuneh Mengistu, Amanuel Berhanu Kotisso, Dawit Zena, Saymen Tsegaye Gebreeyesus, Tadesse Mulusew Gared, Nebyu Samuel Chekol, Ebrahim Umer Muhammed   +9 more
wiley   +1 more source

Analysis of Isoniazid, Streptomycin and Ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco

Journal of Infection in Developing Countries, 2009
Background: Drug-resistant tuberculosis is a major problem worldwide. Based on the knowledge of specific mutations occurring in Mycobacterium tuberculosis genome, drug resistance can be detected earlier.
Imane Chaoui, Radia Sabouni, Moussa Kourout, Annemie M. Jordaan, Ouafae Lahlou, Rajae Elouad, Mohammed Akrim, Thomas C. Victor, Mohammed Elmzibri   +8 more
doaj   +1 more source